Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig.
Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig.
复制标题
通过抗 CD4 与 CTLA4Ig 联合诱导高反应大鼠对小肠同种异体移植物的耐受。
DOI：
10.1097/00007890-199612150-00001
复制
发表时间：
1996
期刊：
影响因子：
6.2
通讯作者：
Fathman,CG
中科院分区：
文献类型：
--
作者：
Yin,DP;Sankary,HN;Williams,J;Krieger,N;Fathman,CG
本研究旨在探讨围手术期联合抗CD4和人(H)CTLA4Ig治疗在预防接受ACI移植物的高应答Lewis大鼠小肠移植排斥反应中的有效性。抗CD4(5 mg/kg×4d)或hCTLA4Ig(0.5 mg/只/只大鼠×2d)单独应用可延缓但不能预防ACI大鼠小肠移植排斥反应。所有移植物分别在18d和10d内被排斥。然而，抗CD4(5 mg/kg×4天)联合hCTLA4Ig(0.5 mg/只大鼠×2天)方案可使ACI同种异体小肠移植物无限期存活。第二个供者匹配的心脏移植被永久接受，而第三方(Spraogue-Dawley)同种异体心脏移植被耐受者拒绝。这些数据表明，这两种试剂在预防同种异体小肠移植排斥反应方面产生了协同作用。
This study was designed to investigate the effectiveness of combined perioperative anti-CD4 and human (h) CTLA4Ig therapy in preventing allorejection of small bowel transplantation in high-responder Lewis rat recipients of ACI grafts. Anti-CD4 (5 mg/kg× 4 days) or hCTLA4Ig (0.5 mg/rat× 2 days) therapy alone delayed, but did not prevent, allograft rejection after small bowel transplantation of ACI into Lewis rats. All grafts were rejected in 18 and 10 days, respectively. However, a regimen of anti-CD4 (5 mg/kg× 4 days) combined with hCTLA4Ig (0.5 mg/rat× 2 days) allowed indefinite survival of ACI small bowel allografts. Second donor-matched heart grafts were permanently accepted, whereas third-party (Sprague-Dawley) heart allografts were rejected by the tolerant recipients. These data suggest that these two reagents produced a synergistic effect in preventing allorejection of small bowel transplantation.